Rigosertib

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Webcast, Interest, Gynecologic Oncology Group, Therapy, ASH, Rigosertib, Protein, Breast cancer, Patient, Mantle cell lymphoma, GOG, Research, FDA, Pharmacology, Neutropenia, SCC, Diarrhea, Ovarian cancer, Cancer, Development, Internet, Society, News, Face, Pharmaceutical industry, Birth control, Video game

NEWTOWN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today reported third quarter 2023 financial results and provided an update on recent pipeline progress. Management plans to host a conference call and live webcast at 4:30 p.m. ET today to discuss these results.

Key Points: 
  • ET on Tuesday, November 14, 2023
    NEWTOWN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today reported third quarter 2023 financial results and provided an update on recent pipeline progress.
  • “Onconova has made excellent progress in the third quarter of 2023.
  • Research and development expenses were $2.5 million for the third quarter of 2023, compared with $3.6 million for the second quarter of 2022.
  • General and administrative expenses were $2.7 million for the third quarter of 2023, compared with $2.1 million for the second quarter of 2022.

Onconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma

Retrieved on: 
Tuesday, February 7, 2023
AACR, Concha bullosa, VII, Cancer, PLK1, Rigosertib, Risk, Conference, Patient, Skin, FDA, SCC, Neoplasm, Radiation, Death, Infection, Thomas Jefferson University, Therapy, American Association for Cancer Research, Pharmaceutical industry, RDEB

NEWTOWN, Pa., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the second of two evaluable participants in an investigator-initiated Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa (RDEB-associated SCC) achieved a complete response of all cancerous skin lesions following 4 treatment cycles and remains on oral rigosertib.

Key Points: 
  • The Company previously announced that the RDEB-associated SCC program’s first evaluable participant achieved a RECIST-defined complete response.
  • Both of the program’s evaluable participants remain on therapy, with the first participant in complete remission with no signs of metastatic disease for more than 18 months.
  • Rigosertib continues to demonstrate a favorable safety profile in this indication that is similar to that displayed in prior studies in other indications.
  • In addition, these findings may have important implications beyond this orphan indication, as they and prior preclinical data demonstrate rigosertib’s activity against the PLK1 protein.

Onconova Therapeutics Announces Updated Data from Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-mutated Non-Small Cell Lung Cancer at the ESMO Congress 2022

Retrieved on: 
Monday, September 12, 2022
ICI, Securities Exchange Act of 1934, Response evaluation criteria in solid tumors, Risk, Safety, Mount Sinai, Hematology, NSCLC, Drug Quality and Security Act, Nivolumab, CR, Assistant professor, Company, MOA, Poster, Population, European Society for Medical Oncology, Private Securities Litigation Reform Act, Icahn School of Medicine at Mount Sinai, Securities Act of 1933, Therapy, Neoplasm, Lung cancer, Patient, Cancer, Rigosertib, Oncology, Terminology, Annual report, Progression-free survival, ESMO, Diagnosis, NASDAQ, KRAS, GLOBE, Congress, PR, Pharmaceutical industry, Medical imaging, Risk management, Medicine

In addition, the ESMO data demonstrated activity in multiple patients with bothlow PD-L1 expression at diagnosis and STK11/LKB1 co-mutations, both poor predictive features for current lung cancer treatments."

Key Points: 
  • In addition, the ESMO data demonstrated activity in multiple patients with bothlow PD-L1 expression at diagnosis and STK11/LKB1 co-mutations, both poor predictive features for current lung cancer treatments."
  • The ESMO poster (#1018P) is titled Phase 1/2 Trial of Rigosertib and Nivolumab for KRAS Mutated Non-Small Cell Lung Cancer (NSCLC) Patients.
  • Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer.
  • The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

PI3K inhibitors Drug Pipeline Market Research Report 2022: Insights About 100+ Companies and 100+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Friday, February 11, 2022
Health, Pharmaceutical, Endometrial cancer, TG, CK1, Patient, Colorectal cancer, Cancer, CLL, NHL, Rigosertib, III, Clinical trial, Therapy, Umbralisib, USD, Pfizer, Acquisition, PI3K, Premium, Discovery, News, II, Pharmaceutical industry, Phase

This report provides comprehensive insights about 100+ companies and 100+ pipeline drugs based on PI3K inhibitors pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 100+ companies and 100+ pipeline drugs based on PI3K inhibitors pipeline landscape.
  • This segment of the PI3K inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery.
  • This segment of the report provides insights about the different PI3K inhibitors drugs segregated based on following parameters that define the scope of the report.
  • The companies which have their drug candidate based on PI3K inhibitors in the most advanced stage, i.e.

Onconova Therapeutics Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer

Retrieved on: 
Wednesday, September 22, 2021
Rigosertib, Therapy, Securities Act of 1933, Oncology, Pleural cavity, Second, Standard of care, Nivolumab, Patient, Melanoma, Icahn School of Medicine at Mount Sinai, Risk, Hematology, Annual report, Drug Quality and Security Act, Private Securities Litigation Reform Act, NASDAQ, Cancer, RAS, Mount Sinai, NSCLC, Principal, Company, Terminology, Center, Large-cell lung carcinoma, Duke Cancer Institute, Drug development, Hyponatremia, Survival, Safety, KRAS, Securities Exchange Act of 1934, PRS, GLOBE, Assistant professor, Public relations, Pharmaceutical industry, Risk management, Medical device

NEWTOWN, Pa., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced preliminary safety and efficacy data from an investigator-initiated Phase 1/2a trial of oral rigosertib plus the immune checkpoint inhibitor nivolumab in advanced KRAS mutated (KRAS+) non-small cell lung cancer (NSCLC). The data, which are being featured in a presentation at the 3rd Annual RAS Targeted Drug Development Summit, support the potential anti-cancer activity of rigosertib-nivolumab combination therapy in this indication and show that the doublet has been well tolerated to-date. Three quarters of patients enrolled in the trial have failed two or more lines of prior therapy and all have failed immune checkpoint inhibitors in various combinations.

Key Points: 
  • Radiographic responses were seen across multiple KRAS variants, which potentially differentiates rigosertib from other RAS pathway modulators that target particular KRAS mutations.
  • These responses were observed at the primary tumor site as well as metastatic sites such as the pleura and bone.
  • Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer.
  • The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Chronic Myelomonocytic Leukemia Clinical Trial Pipeline Highlights 2019 - Global Forecast to 2024 by Clinical Trial Stage, Drug Mechanism Class, Company - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 13, 2019
Health, Clinical trials, Oncology, Pharmaceutical, Myeloid leukemia, Health, Drug discovery, Medicine, Myelomonocyte, Leukemia, Clinical trial, Monocytic leukemia, Triciribine, Rigosertib

The "Global Chronic Myelomonocytic Leukemia Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Chronic Myelomonocytic Leukemia Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.
  • Chronic Myelomonocytic Leukemia Pipeline Highlights - 2019, provides most up-to-date information on key pipeline products in the global Chronic Myelomonocytic Leukemia market.
  • It covers emerging therapies for Chronic Myelomonocytic Leukemia in active clinical development stages including early and late stage clinical trials.
  • The report provides Chronic Myelomonocytic Leukemia pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.